[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575638":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":12,"centralContacts":34,"locations":12,"responsibleParty":40,"collaborators":12,"id":44,"slug":12,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":12,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":12,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":12,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":12},{"fullName":5,"class":6},"Future University in Egypt","OTHER",[8,13,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","The patient will not be administered with any drug\u002Fplacebo",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention","EXPERIMENTAL","1mg of folic acid",[18],"Drug: Folic Acid 1 Mg Oral Tablet",{"label":20,"type":15,"description":21,"interventionNames":22},"Treatment","5mg of folic acid",[23],"Drug: Folic Acid 5 Mg Oral Tablet",[25,30],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":12},"DRUG","Folic Acid 1 Mg Oral Tablet","1 mg oral folic acid tablet",[14],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":12},"Folic Acid 5 Mg Oral Tablet","5 mg oral folic acid tablet",[20],[35],{"name":36,"role":37,"phone":38,"phoneExt":12,"email":39},"Fatma Abdalkarim Ibrahim, Bachelor's","CONTACT","01005337309","fatma.ibrahim@fue.edu.eg",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Fatma Abdalkarim","Teaching Assistant- Pharmacy Practice & Clinical Pharmacy","100575638",false,"NCT06774885","ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS","Inclusion Criteria:\n\n* Females older than 18 years\n* Diagnosed with confirmed breast cancer and currently treated with an adjuvant endocrine\n* Experiencing bothersome hot flashes at least 14 times\u002Fweek\n* Taking the treatment within 6 months to two years.\n\nExclusion Criteria:\n\n* Known hypersensitivity to folic acid\n* Patients who have been treated with selective serotonin reuptake inhibitors (SSRIs) within the past 30 days.\n* Renal impairment is defined as a serum creatinine level greater than 2 mg\u002Fld..\n* Significant liver disease: Indicated by liver enzyme levels exceeding two times the upper limit of normal.\n* Metastatic breast cancer\n* Taking other medication for hot flashes\n* Medications inducing hot flashes such as (Clomiphene, Opioids, Nifedipine, Prednisone)","FEMALE","18 Years","75 Years",{"count":53,"type":54},120,"ESTIMATED","INTERVENTIONAL",[57],"PHASE3","The study's objective is to investigate the role of folic acid administration in the management of hot flashes associated with adjuvant endocrine therapy in patients with breast cancer.",[60],"THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS",[62,63,64,65],"Breast cancer","Hot flashes","Endocrine therapy","Folic acid","NOT_YET_RECRUITING","2025-01-09",{"date":69,"type":70},"2025-01-14","ACTUAL",{"date":72,"type":54},"2025-02-09",{"date":74,"type":54},"2025-08",{"name":5,"class":6}]